Exact Sciences Future Growth
Future criteria checks 4/6
Exact Sciences is forecast to grow earnings and revenue by 67.2% and 11.2% per annum respectively. EPS is expected to grow by 67.3% per annum. Return on equity is forecast to be 5.7% in 3 years.
Key information
67.2%
Earnings growth rate
67.3%
EPS growth rate
| Biotechs earnings growth | 24.7% |
| Revenue growth rate | 11.2% |
| Future return on equity | 5.7% |
| Analyst coverage | Good |
| Last updated | 24 Jun 2024 |
Recent future growth updates
Recent updates
Exact Sciences: Still No Reason To Own
Jun 11Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive
Jun 02
An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued
Feb 23Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel
Jan 08Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate
Nov 15Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt
Oct 04An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued
Aug 14Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt
Jun 15Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)
Apr 26We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt
Feb 23An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 45% Undervalued
Jan 10Would Exact Sciences (NASDAQ:EXAS) Be Better Off With Less Debt?
Oct 31Exact Sciences: Price Is Yet To Catch Up As Management Draws Profitability Plans
Oct 13Exact Sciences: Negative EPS And Free Cash Flow, More Downside Likely
Aug 15Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3,623 | 129 | 536 | 632 | 15 |
| 12/31/2025 | 3,221 | -32 | 336 | 422 | 22 |
| 12/31/2024 | 2,831 | -203 | 25 | 167 | 22 |
| 3/31/2024 | 2,535 | -240 | -20 | 112 | N/A |
| 12/31/2023 | 2,500 | -204 | 32 | 156 | N/A |
| 9/30/2023 | 2,406 | -282 | -24 | 139 | N/A |
| 6/30/2023 | 2,301 | -432 | -108 | 73 | N/A |
| 3/31/2023 | 2,200 | -517 | -298 | -88 | N/A |
| 12/31/2022 | 2,084 | -624 | -438 | -224 | N/A |
| 9/30/2022 | 2,005 | -716 | -443 | -300 | N/A |
| 6/30/2022 | 1,938 | -735 | -437 | -300 | N/A |
| 3/31/2022 | 1,852 | -745 | -330 | -199 | N/A |
| 12/31/2021 | 1,767 | -596 | -238 | -102 | N/A |
| 9/30/2021 | 1,760 | -793 | -117 | 34 | N/A |
| 6/30/2021 | 1,712 | -829 | 30 | 156 | N/A |
| 3/31/2021 | 1,546 | -720 | 19 | 109 | N/A |
| 12/31/2020 | 1,491 | -824 | 71 | 136 | N/A |
| 9/30/2020 | 1,321 | -327 | -89 | 0 | N/A |
| 6/30/2020 | 1,131 | -165 | -238 | -111 | N/A |
| 3/31/2020 | 1,062 | -136 | -262 | -87 | N/A |
| 12/31/2019 | 876 | -213 | -284 | -112 | N/A |
| 9/30/2019 | 724 | -216 | -271 | -88 | N/A |
| 6/30/2019 | 623 | -221 | -248 | -62 | N/A |
| 3/31/2019 | 526 | -219 | -250 | -105 | N/A |
| 12/31/2018 | 454 | -175 | -219 | -69 | N/A |
| 9/30/2018 | 399 | -143 | -203 | -69 | N/A |
| 6/30/2018 | 353 | -124 | -167 | -70 | N/A |
| 3/31/2018 | 308 | -119 | -158 | -77 | N/A |
| 12/31/2017 | 266 | -114 | N/A | -72 | N/A |
| 9/30/2017 | 214 | -130 | N/A | -98 | N/A |
| 6/30/2017 | 169 | -141 | N/A | -118 | N/A |
| 3/31/2017 | 133 | -155 | N/A | -121 | N/A |
| 12/31/2016 | 99 | -167 | N/A | -130 | N/A |
| 9/30/2016 | 79 | -170 | N/A | -133 | N/A |
| 6/30/2016 | 63 | -175 | N/A | -145 | N/A |
| 3/31/2016 | 50 | -169 | N/A | -141 | N/A |
| 12/31/2015 | 39 | -158 | N/A | -134 | N/A |
| 9/30/2015 | 27 | -150 | N/A | -135 | N/A |
| 6/30/2015 | 14 | -139 | N/A | -119 | N/A |
| 3/31/2015 | 6 | -120 | N/A | -104 | N/A |
| 12/31/2014 | 2 | -100 | N/A | -81 | N/A |
| 9/30/2014 | 1 | -80 | N/A | -60 | N/A |
| 6/30/2014 | 2 | -59 | N/A | -46 | N/A |
| 3/31/2014 | 3 | -52 | N/A | -40 | N/A |
| 12/31/2013 | 4 | -47 | N/A | -40 | N/A |
| 9/30/2013 | 4 | -48 | N/A | -40 | N/A |
| 6/30/2013 | 4 | -50 | N/A | -43 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EXAS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).
Earnings vs Market: EXAS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: EXAS is expected to become profitable in the next 3 years.
Revenue vs Market: EXAS's revenue (11.2% per year) is forecast to grow faster than the US market (8.6% per year).
High Growth Revenue: EXAS's revenue (11.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EXAS's Return on Equity is forecast to be low in 3 years time (5.7%).